59 results about "Platelet aggregation" patented technology

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

The invention discloses a medicine formula for preventing cerebral infarction and promoting rehabilitation and a preparation method thereof, and belongs to the technical field of preparation of medicines for preventing cerebral infarction, the medicine formula comprises the following raw materials by weight: 10-15 parts of flatstem milkvetch seed, 10-15 parts of dodder, 10-15 parts of tortoise plastron, 10-12 parts of red peony root, 6-9 parts of safflower, and 15-30 parts of red sage root. According to the invention, the flatstem milkvetch seed, the semen cuscutae and the tortoise plastron are used for nourishing liver and kidney, replenishing essence and benefiting marrow, so that the traditional Chinese medicine theory that kidney dominates bone marrow generation and brain is marrow sea is met, and brain function decline is improved from the source; meanwhile, the radix salviae miltiorrhizae, the radix paeoniae rubra and the flos carthami have the effects of promoting blood circulation to remove blood stasis, activating meridians to stop pain, effectively improving brain microcirculation, inhibiting platelet aggregation and reducing blood viscosity, and supplement each other to achieve the effects of strengthening the body resistance to eliminate pathogenic factors and treating both symptoms and root causes, so that the traditional Chinese medicine composition can be used for preventing cerebral infarction of high-risk groups and is also suitable for functional recovery in the rehabilitation period after cerebral infarction.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The invention provides a micro-fluidic chip for detecting platelet aggregation function, and relates to the technical field of platelet aggregation function detection.The micro-fluidic chip comprises a chip body, the chip body is provided with at least one group of detection parts, and each group of detection parts comprises a sample adding groove and at least one group of detection units; the detection unit comprises a coating runner and a reaction cavity; the inner wall of the coating flow channel is coated with an activating agent coating, and the length extending direction of the coating flow channel is inclined relative to the radial direction with the rotation center as the circle center, so that the proximal end and the distal end of the coating flow channel are located on different radial lines with the rotation center as the circle center respectively. Through the arrangement, local retention or dead zones are avoided, the detection efficiency is improved, the dissolution rate of the activator is effectively improved, the dissolution rate of an activator coating is more than 5 mu g / s, the activator is ensured to be fully dissolved, the error absolute value of the final concentration of the activator in a sample is less than 6%, the detection error is reduced, and the detection accuracy is improved.

The present application relates to the technical field of in vitro detection, and particularly relates to a platelet aggregation function detection reagent and application thereof.The platelet aggregation function detection reagent provided by the present application comprises a fibrin activator and an ADP reagent, the fibrin activator adopts a novel high-purity porcine dermal collagen polypeptide component Prionex, and the combination with glycine significantly improves the stability of the fibrin activator, the platelet inhibitor tirofiban is used in combination with PEG6000, the accuracy of the detection result is improved, and the sensitivity to the anti-platelet aggregation drug is improved; the ADP reagent adopts chitosan, the activity and stability are improved, and the ADP reagent can be widely applied to clinical diagnosis of platelet aggregation function.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The invention relates to the technical field of medicinal chemistry, in particular to a novel carbamate fumarate, and a crystal form, an amorphous form and a preparation method thereof. The carbamate fumarate and the crystal form and the amorphous form thereof have high stability and solubility and low hygroscopicity, the medicinal performance is improved, the platelet aggregation resisting effect is better, the medicine effect is higher, and clinical application of the medicine is facilitated.

Wound dressings and methods for treating a wound are provided. The wound dressing can have an environment-facing side that includes a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor and a wound-facing side including a biocompatible resinous matrix and an antifibrinolytic agent. The wound dressing can promote fibrin formation and rapid platelet aggregation, and has antimicrobial properties. The dressing can be applied directly to the wound.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

The application discloses a sports nutrition food composition for blood vessel health and post-exercise recovery. Each 40g contains soybean protein isolate, whey protein, resistant dextrin, inulin, ginkgo biloba extract, hawthorn extract, grape seed extract, sea buckthorn peptide, natto powder (containing natto kinase), coenzyme Q10, natural vitamin E, vitamin C, bacillus subtilis DE111 and mineral probiotic premix. The application realizes blood vessel cleaning and post-exercise recovery through the synergy of multiple pathways such as direct thrombolytic effect of natto kinase, anti-platelet aggregation of ginkgo biloba / hawthorn / grape seed, protection of blood vessel endothelium by coenzyme Q10 / VE / VC, and regulation of intestinal tract by bacillus subtilis DE111. In-vitro thrombolysis experiment shows that the composition has clear fibrinolytic activity. All components meet the national standard of sports nutrition food, are safe and compliant, and are suitable for people with thrombosis risk and people who need blood vessel repair after high-intensity exercise.

The present application relates to the technical field of platelet aggregation detection, and specifically discloses a clinical platelet aggregation detection carrier, which comprises an instrument body and further comprises: a detection assembly arranged inside the instrument body, which is used for detecting different types of samples of lipemia, anemia and normal blood and selecting centrifugal operation of the blood samples; the detection assembly can detect different types of samples of lipemia, anemia and normal blood, and can automatically indicate whether centrifugal operation of the blood is needed according to the types of the detected samples; through the sampling assembly, the blood samples at different layer depths can be automatically adjusted according to the lipemia, anemia and normal blood samples detected by the detection assembly; through the agent adding assembly, the amount of the added inducing agent can be automatically adjusted according to the sample amount taken by the sampling assembly, so that the concentration of the mixed inducing agent reaches the specified range, thereby improving the detection accuracy of the platelet aggregation degree.

The utility model relates to the technical field of apical surgery, in particular to an in-vitro compression hemostasis device for apical surgery, which comprises placing cloth, adjustable elastic ropes are fixedly mounted on four sides of the placing cloth, an ice bag is arranged on one side of the placing cloth, gauze is wound on the outer sides of the placing bag and the ice bag, and the gauze is wound on the outer side of the placing cloth. A medical proof fabric is adhered to the interface of the gauze; according to the scheme, the placing cloth and the four adjustable elastic ropes are arranged, the ice bag can be placed on one side to wrap the ice bag, so that a patient can wear the ice bag conveniently, tight attachment of the ice bag and proper pressure can directly act on a bleeding part, the blood flow speed is reduced, platelet aggregation at a wound is promoted, thrombus is formed, bleeding is effectively stopped, and the patient can be prevented from being injured. The ice bag can be tightly attached to the body of a patient through the adjustable elastic rope and is not prone to slipping or shifting, and the wearing comfort and stability are improved.

The application provides an emergency department wound hemostasis device, and relates to the technical field of wound hemostasis. The emergency department wound hemostasis device comprises an inflation hemostasis air bag, and the lower surface of the inflation hemostasis air bag is fixedly connected with a constant-temperature film bag. When working, the second liquid pump is started, the second liquid pump extracts water in the constant-temperature water storage tank through the second liquid pipeline, the water enters the inside of the constant-temperature film bag through the fourth liquid pipeline, the temperature of the wound is ensured, meanwhile, the first liquid pump is started, the first water valve on the first liquid pipeline is opened, the water in the constant-temperature film bag is extracted through the first liquid pipeline, and finally the water enters the inside of the constant-temperature water storage tank, so that the water in the constant-temperature film bag is always in a constant-temperature state, the temperature is close to the optimum point of the thrombin reaction, the platelet aggregation and fibrin formation can be accelerated, the method is safe and efficient, the tissue damage can be minimized, and the hemostasis speed is accelerated.

This invention belongs to the field of traditional Chinese medicine (TCM) technology, specifically relating to a TCM composition with detoxifying and uterus-warming effects and its application in the preparation of external products. The medicinal component of this external TCM product is composed of fenugreek, amethyst, rose, pomegranate seed, centella asiatica, long pepper, five-finger peach, lycopodium, litchi seed, and achyranthes bidentata. Animal experiments show that this product can significantly reduce the number of writhing movements in animals with cold-induced blood stasis type dysmenorrhea, lower COX-2 and PGE2 levels in the uterus, and improve peritoneal inflammation, demonstrating good detoxifying, blood stasis-removing, menstruation-regulating, and pain-relieving effects. Regarding blood rheology, it exhibits the effects of inhibiting platelet aggregation, dilating blood vessels, reducing blood viscosity, and balancing TXA2 and PGI2 levels, reflecting its effects of warming the kidneys and uterus, and strengthening the body's foundation. In summary, the TCM composition of this invention and its prepared external product can warm the kidneys and uterus, promote diuresis and eliminate turbidity, providing a novel TCM external application solution for the clinical treatment of cold-induced blood stasis type dysmenorrhea.

Wound dressings and methods for treating a wound are provided. The wound dressing can have an environment-facing side that includes a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor and a woundfacing side including a biocompatible resinous matrix and an antifibrinolytic agent. The wound dressing can promote fibrin formation and rapid platelet aggregation, and has antimicrobial properties. The dressing can be applied directly to the wound.

The invention discloses a preparation process of a freeze-dried platelet aggregation activation reagent, and relates to the technical field of medical reagent preparation, and the preparation process comprises the following steps: (1) preparing trehalose grafted chitosan; (2) preparing phenylboronic acid-trehalose-chitosan; (3) preparing a multifunctional freeze-drying protection carrier; (4) preparing a supramolecular complex binding solution; and (5) sub-packaging the supramolecular complex binding liquid, and performing programmed freeze-drying to obtain the freeze-dried platelet aggregation activation reagent. According to the invention, an environmental response network is constructed to anchor the conformation of the active substance, and a long chain with an antioxidant group and a programmed freeze-drying technology are cooperated, so that free radicals are removed, a porous structure is maintained, and the redissolution efficiency, the biological activity and the long-term storage stability of the reagent are improved.

This invention relates to the interdisciplinary field of biomedical detection and Internet of Things (IoT) sensing technology, specifically disclosing a platelet-rich plasma concentration detection system based on IoT biosensors. The system includes a microfluidic sensor chip, a multi-frequency electrochemical impedance spectroscopy (MES) acquisition unit, a cell morphology identification module, an IoT communication unit, and a remote data processing server. It monitors platelet dynamic aggregation in real time through a three-electrode system, and combines high-dimensional features of broadband impedance spectroscopy with a pre-trained convolutional neural network model to accurately distinguish between simple platelet aggregates, platelet-leukocyte complexes, and microthrombus structures. Furthermore, it leverages the IoT architecture to complete encrypted data upload, remote model optimization, and intelligent coagulation risk assessment. Through the above technical solutions, this invention improves the sensitivity, specificity, and clinical applicability of the detection, constructing a closed-loop blood monitoring system from bedside detection to cloud-based decision support.

The present application provides a Bifidobacterium breve. The strain has high yield of acetoin and has milk clotting function. The present application provides a fermenting agent comprising the Bifidobacterium breve. The preparation method of the fermenting agent is also provided. The present application also provides a fermented ovine colostrum, which contains a plurality of functional polypeptides. The present application also provides a preparation method of the fermented ovine colostrum. The method can simultaneously ensure high retention rate of nutrients in the ovine colostrum. The present application also provides a polypeptide. The polypeptide can inhibit angiotensin converting enzyme activity, improve vascular endothelial function or inhibit platelet aggregation, and has cardiovascular protection ability. The present application also provides a polypeptide composition. The present application also provides application of the Bifidobacterium breve, the polypeptide and / or the fermented ovine colostrum in the field of food or medicine for helping to enhance immunity.

The utility model relates to the technical field of platelet aggregation function detection, and discloses a platelet aggregation function detection reagent card which comprises a shell. The shell is provided with a sample bin, a separation area, a poor platelet containing cavity and a rich platelet containing cavity, the sample bin is provided with an opening facing the outside, an inlet of the separation area is communicated with the sample bin through a liquid inlet channel, and the separation area comprises a first separation channel communicated with the poor platelet containing cavity and a second separation channel communicated with the rich platelet containing cavity. The first separation channel and the second separation channel are filled with first filler and second filler respectively, and the aperture formed by the second filler is larger than that of the first filler. The operation process is simplified, and the separation efficiency is improved, so that the subsequent detection efficiency is improved.

Provided are novel carbamate fumarate, a crystalline form and amorphous form thereof, and a preparation method therefor. The carbamate fumarate and the crystalline form and amorphous form thereof have high stability and high solubility, low hygroscopicity, and improved pharmaceutical properties, and achieves a better anti-platelet aggregation effect and higher efficacy, thereby facilitating the clinical application of drugs.

The present application relates to composition for nourishing the kidneys and its preparation method. More specifically, the present application relates to an Oyster peptide kidney-nourishing formula composition and preparation method. The composition and preparation method are designed to address the technical issues in traditional Chinese medicine where the kidney-nourishing effects are slow to appear, treatment takes a long time, boiled medicine has a poor taste, and it's inconvenient to carry. An Oyster peptide kidney-nourishing formula composition, comprising the following medicines: oyster peptide, pumpkin seed extra, epimedium extract, maca extract, tribulus terrestris extract, eurycomanone, arginine, lycopene, VB2, VB6, selenium and zinc. The product created by this application has several functions such as increasing male serum testosterone levels, regulating blood lipids, inhibiting platelet aggregation, improving symptoms of hyperglycemia, enhancing human immunity, and promoting metabolism.

The utility model relates to the technical field of platelet aggregation function detection, and discloses a platelet aggregation function and state detection device and system.The device comprises a shell, the shell is provided with a sample bin, a buffer area, a first containing cavity and a second containing cavity, and the sample bin is provided with an opening facing the outside; an inlet of the buffer area is communicated with the sample bin through a liquid inlet channel, the first containing cavity and the second containing cavity are arranged at the bottom of the shell in parallel and connected to an outlet of the buffer area, and the first containing cavity and the second containing cavity are provided with a first transparent window and a second transparent window which face the same direction respectively. The first containing cavity is suitable for containing a to-be-judged sample, and the second containing cavity is suitable for containing a to-be-detected sample. Whether the platelet aggregation function detection result is effective or not is judged by judging whether the platelet is aggregated in advance or not according to the judgment sample, so that the platelet aggregation function detection result is ensured to be correct, and the accuracy of the platelet aggregation function detection result is improved.

This invention provides a chitosan hemostatic material for rapid arterial hemostasis, its preparation process, and its applications, relating to the field of medical technology. The chitosan hemostatic material prepared by this invention can significantly shorten hemostasis time, maintain stable adhesion to the wound surface even under the impact of arterial blood flow, and is not easily detached, exhibiting strong wet adhesion and erosion resistance. The chitosan hemostatic material prepared by this invention not only improves the mechanical strength of the material but also provides more bioactive sites, activating intrinsic coagulation pathways and platelet aggregation, thereby improving hemostasis efficiency and showing significant advantages in emergency applications for arterial bleeding. The chitosan hemostatic material prepared by this invention combines rapid coagulation and stable hemostasis, and has good biocompatibility, controllable degradation, reduced inflammatory response, and high safety. The porous structure of the chitosan hemostatic material prepared by this invention is beneficial for tissue repair, does not adhere to other tissues, promotes healing, and has promising application prospects.

The application discloses a preparation method of honokiol-tetramethylpyrazine eutectic crystal, which comprises the following steps: mixing honokiol and tetramethylpyrazine, ball milling / stirring, and drying to obtain honokiol-tetramethylpyrazine eutectic crystal. The application further discloses honokiol-tetramethylpyrazine eutectic crystal prepared by the above method. The application further discloses a composition comprising the above honokiol-tetramethylpyrazine eutectic crystal and honey. The application further discloses the use of the above honokiol-tetramethylpyrazine eutectic crystal or the above composition in the preparation of drugs for treating cardiovascular and cerebrovascular diseases, resisting platelet aggregation and resisting tumors.

The invention relates to application of alpha-pyrone compounds in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The alpha-pyrone compound separated from deep-sea fungus fermentation liquor is applied to the field of prevention and treatment of thrombotic diseases for the first time. After detection, it is found that the compounds 6-((2S, 3S)-2, 3-dihydroxy-2-butyl)-3-methyl-2H-pyran-2-one and 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one can significantly increase the red blood volume of zebra fish and relieve tail thrombus, and have the ability to resist thrombus, and the compounds 6-((2S, 3S)-2, 3-dihydroxy-2-butyl)-3-methyl-2H-pyran-2-one and 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one have the ability to resist thrombus; further detection shows that the 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one can improve the blood flow velocity of a thrombus area and inhibit platelet aggregation, and is low in action concentration, so that the 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one is small in toxic and side effects, has the potential of developing novel antithrombotic drugs, health-care foods and functional foods, and is wide in market application prospect.

The invention provides rhizoma bletillae gel as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine preparations. In the rhizoma bletillae gel provided by the invention, the tea polyphenol and rhizoma bletillae are compounded for use and synergistically resist inflammation, so that red, swollen and pain caused by inflammation are effectively relieved, and wound healing is accelerated. In addition, the rhizoma bletillae and the tea polyphenol generate a synergistic antibacterial effect, so that the probability of wound infection is reduced; the compounding use of rhizoma bletillae and tea polyphenol also inhibits the excessive deposition of collagen, reduces the scar area, and reduces the scar hyperplasia degree. Moreover, the three auxiliary materials including the polyhydric alcohol cosolvent, the water-soluble humectant and the polymer hydrogel are compounded for use, and after the rhizoma bletillae gel is externally applied, a layer of gel protection film can be formed on the surface of a wound within a short time, so that invasion of pathogenic bacteria such as staphylococcus aureus and escherichia coli can be physically isolated, external friction stimulation can be reduced, and the wound healing effect is improved. Meanwhile, platelet aggregation is promoted, the blood coagulation time is shortened, and the risk of wound exudation and bleeding in the early stage of burn / scald is reduced.